ProQuant™ is now offered by RxCelerate following the acquisition of the proteomics team from Methuselah Health in 2022. Methuselah Health was founded in 2015 to discover drugs for age-related diseases driven by proteomic instability, and has developed the world’s most powerful proteomics platform to power its discovery efforts. RxCelerate was founded in 2013 with a vision to provide a bespoke high-quality outsourced drug discovery and development platform. Originally focused on delivering preclinical and in vitro biology services, during the last nine years we have expanded our in-house capabilities to include chemistry, in silico design, systems biology and project and programme management.
World leading proteomics platform
ProQuant™ is a world-leading proprietary platform for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples, delivering precision unachievable by other proteomics platforms.
Learn more about our proprietary technology.
Our Leadership Team
CTO at Methuselah Health UK and previously CEO at Total Scientific, a small CRO specialising in biomarker discovery and VP of R&D at Pronostics, which developed CE-marked multiplex autoantibody assays using barcoded microparticles. David has 30 years experience in developing assays for hard-to-measure proteins and eliminating bias wherever he finds it.
With a wealth of experience gained from performing academic and commercial scientific research as well as managing customer-lead research, Tilly now manages programmes using the ProQuant™ platform within RxCelerate.
Dorothy Hodgkin Building,
Babraham Research Campus,
Babraham, Cambridge CB22 3FH